Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oteseconazole (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2019 Last checked against the ClinicalTrials.gov record.
    • 10 Mar 2018 Results (n=215) assessing efficacy and safety of 4 dosing regimens of oral VT-1161 compared to placebo in women with recurrent vulvovaginal candidiasis, were published in the American Journal of Obstetrics and Gynecology.
    • 23 Oct 2017 According to a Viamet Pharmaceuticals media release, results from this trial will be presented at the International Society for Infectious Diseases in Obstetrics and Gynaecology (ISIDOG) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top